• Neurocrine Biosciences released a new real world retrospective claims analysis on treatment persistence in tardive dyskinesia.
• The study compared INGREZZA (valbenazine) with AUSTEDO XR (deutetrabenazine) in adult patients over a six month period.
• Patients on INGREZZA showed higher continuation rates and lower treatment switching throughout the study window.

Neurocrine Biosciences, listed as NasdaqGS:NBIX, puts this new data in front of investors at a time when the stock trades at $130.81. The company has a 36.0% return over the past year and a 36.0% return over five years, which reflects how the market has priced its position in movement disorder treatments.

For investors watching treatment adoption trends, this real world persistence study adds another datapoint to monitor as payers, clinicians, and patients weigh options in tardive dyskinesia. The ways in which this evidence may influence prescribing patterns, reimbursement decisions, and competitive responses will be important to track over the coming quarters.

Stay updated on the most important news stories for Neurocrine Biosciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Neurocrine Biosciences.

This real world analysis matters because it speaks to how INGREZZA is actually used over time relative to Teva’s AUSTEDO XR, a key competitor in tardive dyskinesia. Higher treatment persistence and lower switching over six months suggest that patients, clinicians, or payers are finding INGREZZA acceptable enough to stay on, which can support more stable prescription volumes. For a neurology-focused company that relies heavily on a few commercial products, evidence like this can be helpful in payer discussions and formulary negotiations, where real world outcomes increasingly sit alongside clinical trial data. Investors comparing Neurocrine to other central nervous system players such as Biogen or Bristol Myers Squibb may view this as another marker of how INGREZZA is positioned in a competitive VMAT2 inhibitor class.

How This Fits Into The Neurocrine Biosciences Narrative

• The persistence data aligns with the narrative that INGREZZA is a core neurology franchise supported by expanded payer access and supports the idea of sustained product leadership in tardive dyskinesia.
• At the same time, the study highlights direct head to head comparison with AUSTEDO XR, underlining the portfolio concentration risk that the narrative already flags if competitors capture more share.
• The analysis focuses on persistence rather than pricing or gross to net trends, so it does not fully address the narrative concerns about payer pushback, rebates, or long term pricing pressure on INGREZZA.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Neurocrine Biosciences to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Continued head to head comparisons with Teva’s AUSTEDO franchise keep competitive pressure front and center, which ties into concerns about portfolio concentration around a single lead product.
• ⚠️ Real world claims data does not fully capture clinical nuance, so any future datasets that are less favorable for INGREZZA could quickly shift perceptions among payers and prescribers.
• 🎁 The higher 6 month treatment persistence and lower switching rates for INGREZZA suggest more durable therapy use, which can support revenue stability in tardive dyskinesia.
• 🎁 The combination of this real world evidence with prior clinical outcomes work may strengthen Neurocrine’s position in discussions with payers and clinicians who are weighing competing VMAT2 inhibitors.

What To Watch Going Forward

From here, it is worth watching how this real world dataset shows up in future commentary from Neurocrine, especially around payer access, formulary wins, and any updates on tardive dyskinesia prescription trends. Investors may also want to track whether Teva or other neurology competitors produce their own comparative data or adjust commercial tactics in response. Any signals on how persistence metrics translate into overall INGREZZA volumes or guidance updates will be important for assessing the durability of Neurocrine’s movement disorder franchise.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Neurocrine Biosciences, head to the community page for Neurocrine Biosciences to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.